Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a significant increase in stock price, rising by 6.23% to HKD 16.37, with a trading volume of HKD 3.5768 million, following the announcement of a potential exclusive agency agreement for its core product TY-9591 with Sichuan Huiyu Pharmaceutical's subsidiary Sichuan Huichenxing [1] Group 1 - The company plans to enter into a potential exclusive agency agreement with Sichuan Huichenxing for TY-9591 in mainland China, excluding Hong Kong, Macau, Taiwan, and other overseas regions [1] - The initial milestone payment under this potential agreement could reach up to RMB 150 million [1] - The company is entering the commercialization phase for TY-9591, and if the agency arrangement is finalized, it will leverage Sichuan Huichenxing and Sichuan Huiyu's extensive sales and distribution network [1] Group 2 - Sichuan Huiyu is a mature pharmaceutical enterprise with a complete industrial chain and extensive experience in drug agency and sales in China [1] - The company believes that this arrangement will enhance the sales and revenue of TY-9591, accelerate market penetration, reduce costs associated with establishing new sales channels, and strengthen its brand image through collaboration with a well-known pharmaceutical company [1]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) announced a potential exclusive agency agreement for its core product TY-9591 with Sichuan Huicheng Pharmaceutical Co., Ltd. (Sichuan Huicheng), which is a wholly-owned subsidiary of Sichuan Huicheng [1] Group 1 - Sichuan Huicheng's board approved the potential agency agreement for TY-9591, which will allow Sichuan Huicheng to act as the exclusive agent in mainland China, excluding Hong Kong, Macau, Taiwan, and other overseas regions [1] - The initial milestone payment for this agreement could reach up to RMB 150 million [1] - The company is entering the commercialization phase for TY-9591, and if the agency arrangement is finalized, it will leverage Sichuan Huicheng's extensive sales and distribution network [1] Group 2 - Sichuan Huicheng is a mature pharmaceutical enterprise with a complete industry chain and rich experience in drug agency and sales in China [1] - The company believes that this arrangement will enhance the sales and revenue of TY-9591, accelerate market penetration, reduce costs associated with establishing new sales channels, and strengthen its brand image through collaboration with a well-known pharmaceutical company [1]

Core Viewpoint - The announcement indicates that Sichuan Huiyu Pharmaceutical Co., Ltd. has approved a potential agency agreement for the core product TY-9591, which could enhance sales and market penetration in China [1] Group 1: Agreement Details - Sichuan Huichen Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Sichuan Huiyu, may be appointed as the exclusive agent for TY-9591 in mainland China, with an initial milestone payment of up to RMB 150 million [1] - The potential agency arrangement is aimed at leveraging the existing sales and distribution network of Sichuan Huichen and Sichuan Huiyu [1] Group 2: Strategic Implications - The arrangement is expected to accelerate market penetration and reduce costs associated with establishing new sales channels for TY-9591 [1] - Collaborating with a well-established pharmaceutical company like Sichuan Huiyu is anticipated to strengthen the company's brand image in the market [1]

TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 內幕消息 與四川匯宇製藥股份有限公司之潛在總代理安排 本公告乃由浙江同源康醫藥股份有限公司（「本公司」，連同其附屬公司統稱「本集 團」）根據香港法例第571章證券及期貨條例第XIVA部項下內幕消息條文及香港聯 合交易所有限公司證券上市規則（「上市規則」）第13.09條作出。 本公司董事（「董事」）會（「董事會」）謹此知悉，四川匯宇製藥股份有限公司（「四 川匯宇」）已於2025年8月26日刊發公告，內容有關其董事會批准四川匯辰昕藥 業有限公司（「四川匯辰昕」）（四川匯宇之全資附屬公司）與本公司就TY-9591（本 公司之核心產品）訂立潛在總代理協議（「潛在總代理安排」）。根據潛在總代理安 排，本公司可同意委任四川匯辰昕為TY-9591在中華人民共和國（不包括香港、澳 門、台灣及任何其他海外地區）的獨家總代理商，初始里程碑付款金額最高可達 人民幣150百萬元。 本公司與四川匯辰昕現就潛在總代理安排之其他商業條款進行磋商，包括但不限 於里程碑、四川匯辰昕付款責任之付款時間表及潛在總代 ...

Core Insights - The report highlights significant changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2]. Group 1: Companies with Increased Holdings - Tongyuan Kang Pharmaceutical-B (02410) saw the largest increase in holdings, up by 5.25%, bringing its total to 14.57% [2]. - ZTE Corporation (00763) experienced a 2.17% increase, resulting in a total holding of 52.34% [2]. - Kaisa New Energy (01108) had a 2.04% increase, with a current holding of 67.68% [2]. - Other companies with notable increases include Lens Technology (06613) (+1.87% to 8.79%) and Jintian Copper (06680) (+1.77% to 23.92%) [2]. Group 2: Companies with Decreased Holdings - Hang Seng China Enterprises (02828) faced the largest decrease, down by 16.78%, now holding 3.33% [2]. - The Yingfu Fund (02800) saw a reduction of 6.51%, with a current holding of 2.61% [2]. - Southern Hang Seng Technology (03033) decreased by 4.40%, now at 58.58% [2]. - Other notable decreases include Nanjing Panda Electronics (00553) (-2.23% to 44.31%) and Hongye Futures (03678) (-0.92% to 63.83%) [2]. Group 3: Five-Day Holding Changes - In the last five trading days, Yimai Sunshine (02522) had the highest increase at 6.09%, reaching 39.65% [3]. - Longpan Technology (02465) increased by 5.49%, now at 50.61% [3]. - Tongyuan Kang Pharmaceutical-B (02410) also increased by 5.32% [3]. - Companies with notable decreases include Dongyang Sunshine Pharmaceutical (06887) (-4.29% to 44.53%) and Zhejiang Shibao (01057) (-2.87% to 55.69%) [3]. Group 4: Twenty-Day Holding Changes - Changfei Optical Fiber (06869) had the largest increase over twenty days, up by 23.37% to 56.18% [4]. - Meizhong Jiahe (02453) increased by 11.80%, now at 37.50% [4]. - Yimai Sunshine (02522) also saw a significant increase of 10.51% [4]. - Companies with notable decreases include Chongqing Steel (01053) (-7.51% to 32.02%) and Dongfang Electric (01072) (-6.56% to 37.36%) [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 有關董事於禁售期進行證券交易之公告 本公告乃由浙江同源康醫藥股份有限公司（「本公司」）根據香港聯合交易所有限公 司證券上市規則（「上市規則」）附錄C3第D.15段作出。 本公司董事（「董事」）會（「董事會」）已獲非執行董事顧虹博士（「顧博士」）告知， 於2025年8月20日，顧博士全資擁有的公司貝沃特醫藥技術（上海）有限公司進行 一項場內交易，出售本公司合共10,000股H股（「H股」），代價為每股H股14.99港 元（「轉讓」），而其於轉讓前並無根據上市規則附錄C3第B.8段之規定事先告知本 公司。由於轉讓，顧博士於本公司之H股實益權益已從約2.20%減至於本公告日期 本公司已發行H股股本總額之2.19%。 根據上市規則附錄C3第A.3段，董事於本公司財務業績刊發的任何日 ...

同源康医药-B(02410.HK)公告，董事会会议将于2025年8月31日(星期日)举行，藉以(其中包括)考虑及批 准公司及其附属公司截至2025年6月30日止6个月的中期业绩及其刊发，以及考虑派发中期股息(如有)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 香港，2025年8月20日 於本公告日期，董事會成員包括執行董事吳豫生博士，非執行董事李鈞博士、顧 虹博士、蔣鳴昱博士、孟曉英博士、何超先生及朱向陽博士，獨立非執行董事張 森泉先生、冷瑜婷博士、許文青博士及沈秀華博士。 （股份代號：2410） 董事會會議日期 浙江同源康醫藥股份有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，董 事會會議將於2025年8月31日（星期日）舉行，藉以（其中包括）考慮及批准本公司 及其附屬公司截至2025年6月30日止六個月的中期業績及其刊發，以及考慮派發 中期股息（如有）。 承董事會命 浙江同源康醫藥股份有限公司 董事長、執行董事兼總裁 吳豫生博士 ...

Market Performance - The Hong Kong stock market indices continued to decline, with the Hang Seng Index falling by 0.57% to 24,980.20, the Hang Seng China Enterprises Index down by 0.67% to 8,945.88, and the Hang Seng Tech Index dropping by 1.26% to 5,472.25, marking a breach of the 25,000-point threshold again [1]. Sector Performance - Large technology stocks showed weak performance, with Kuaishou down nearly 5%, Alibaba down 1.6%, JD.com down 1.46%, and Baidu down 1%. Tencent, NetEase, Meituan, and Xiaomi also experienced declines [3]. - The pharmaceutical sector faced significant adjustments, particularly in internet healthcare and innovative drug stocks, with Tongyuan Kangyi falling nearly 22%, and other notable declines from Gilead Sciences, Nuo Cheng Jianhua, and Fosun Pharma [3]. - Chinese brokerage stocks were collectively weak, with Hongye Futures and Dongfang Securities showing notable declines [3]. Notable Stock Movements - Fuyao Glass surged nearly 14% following its earnings report, indicating strong performance in the glass manufacturing sector [3]. - New consumption concept stocks saw a rise, particularly Pop Mart, which increased by 8.6%, surpassing the 300 HKD mark for the first time [3].

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) experienced a significant stock price increase, attributed to the acceptance of its innovative drug, TY-9591, for a key II phase registration clinical trial report at the 2025 World Lung Cancer Conference (WCLC) [1] Group 1: Company Developments - The company announced that its self-developed innovative drug, TY-9591, targets EGFR mutation-type non-small cell lung cancer (NSCLC) and has shown promising results in clinical trials [1] - TY-9591 is a highly selective small molecule inhibitor aimed at addressing unmet clinical needs for NSCLC patients with brain metastases under current treatment standards [1] Group 2: Clinical Trial Results - Research indicates that TY-9591, as a new generation EGFR-TKI, demonstrates superior efficacy in controlling brain metastases and alleviating symptoms, potentially offering a new and more effective first-line treatment option for EGFR mutation NSCLC patients with brain metastases [1]